On this page
How should an uncontrolled clinical study report describe its findings?
Describe participant selection, treatment, exposure, outcomes and follow-up with explicit denominators and missing-data limitations. Keep interpretation within the design, especially for extensions involving selected participants. An open-label study is not necessarily uncontrolled; inspect the actual comparison before classifying the report.
Before you begin
Uncontrolled clinical studies, including relevant open-label safety or extension studies. Open-label does not automatically mean uncontrolled: inspect the actual design.
What you will prepare: A study report that accounts for selection, exposure, follow-up and outcomes without inventing a concurrent comparison.
Confirm whether a control exists
Read the protocol's design and objectives before classifying the study. An unblinded randomized comparison can still be controlled; a single-arm extension often has no concurrent comparison. M4E places uncontrolled study reports in 5.3.5.2, including relevant studies outside the proposed indication. Do not discard a report because its indication differs or its results are unfavorable.
Gather entry criteria, source-study links for extension participants, treatment history, follow-up rules, protocol/SAP versions and final outputs. Establish whether the report is complete or interim and which participants and dates it represents. Missing follow-up information is a reporting gap, not evidence of no event.
Describe who entered, who remained and for how long
Explain participant selection, prior treatment, exposure during this study, withdrawals and observation time. For an extension, distinguish new participants from those continuing a parent study and document whether identifiers allow cross-study reconciliation. Define outcomes and assessment windows consistently with the analysis plan.
Present results with appropriate denominators and uncertainty, and describe missing assessments and unequal follow-up. Long exposure among participants who remain in a study can coexist with early withdrawal among others. Adapt the report's detail to its role and applicable advice; an uncontrolled design does not automatically authorize an abbreviated or incomplete safety report.
Keep the interpretation within the design
Fictional exercise: a long-term extension has fewer reported events than the parent trial, and the draft concludes that risk falls with duration. Review the different populations, withdrawal patterns, observation periods and collection methods. Describe what was observed and the alternative explanations; do not turn a selected survivor population into proof of declining risk.
If an external benchmark is used, identify its source and comparability limitations rather than presenting it as a randomized control. Reconcile participant and exposure counts with integrated analyses so extension enrollment does not double-count unique people. The useful final report makes the evidence reusable while preserving the limitations of selection and absent concurrent control.
Track participants across the parent study and extension
Use this working map to prevent an apparently reassuring extension result from hiding selection or counting differences.
| Record | Establish | Question before comparison |
|---|---|---|
| Parent relationship | Source study and stable participant mapping | Which people appear in both reports? |
| Extension entry | Eligibility, prior treatment and entry date | Who was selected to continue? |
| Continued exposure | Actual treatment and interruptions | Which period contributes to this analysis? |
| Follow-up | Assessments, withdrawals and missing observations | Who remained observable for each outcome? |
| Integrated use | Unique-person and exposure rules | How is double-counting prevented? |
Review exercise: the extension shows a lower event proportion than the parent trial. Before interpreting a change in risk, compare the populations, observation periods, collection methods and withdrawal patterns. Report the observed findings and the limitations of the comparison; the two percentages do not by themselves establish a time-related causal effect.
Connect the participant map to the integrated safety analysis and the clinical safety summary. Preserve the distinction between unique people and their participation in multiple study periods.
Your preparation checklist
0/4 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Is every open-label trial uncontrolled?
No. Blinding and the presence of a control are different design features. An open-label randomized comparison can still be controlled. Read the protocol’s actual allocation and comparison structure before selecting the report family or describing the study’s interpretive limitations.
Does lower event reporting in an extension prove risk decreases over time?
No. Participants, follow-up, collection methods and withdrawal patterns may differ from the parent study. Describe those differences before comparing results. A selected population remaining in follow-up does not by itself establish a decline in treatment-related risk.
Should participants in a parent study and extension count as two unique people?
No. When an integrated analysis describes unique participants, reconcile identities across the linked studies and apply the defined counting rules. Study participation and exposure periods may be analyzed separately, but that does not make one individual two unique people.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
FDA M4E(R2): The CTD: Efficacy ↗July 2017, Revision 1, final. Module 5, printed pp.56–64. Organization guidance, not a list of studies required for every application. Reopened September 22, 2026.
Guidance
FDA ICH E3: Structure and Content of Clinical Study Reports ↗July 1996 final FDA implementation. Introduction, title page, sections 5–13 and 16. Reopened September 22, 2026; also checked against the ICH Step 4 original. These editorial guides are not agency-endorsed.
Guidance
FDA E3 Questions and Answers (R1) ↗January 2013 final; Q1–Q3 on flexible structure, synopsis and appendices; Q6–Q8 on terminology. Reopened September 22, 2026.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 5.3.5.2. A heading identifies placement, not mandatory applicability.